2021-01-29 20:20
Biovica, active in cancer diagnostics, today announced that the US Food and Drug Administration (FDA) has resumed its review of Biovica’s 510(k)-submission for DiviTum®TKa. “This is fantastic news on our journey to make the test available...
2021-01-18 08:00
DiviTum®TKa has been selected to be included in the new prospective clinical study TIRESIAS, with the aim of investigating if DiviTum®TKa can be used to identify early resistance to treatment by a CDK4/6 inhibitor in combination with an aromatase...
2021-01-16 12:48
Biovica, active in cancer diagnostics, today announced that the US Food and Drug Administration (FDA) has indicated that its previously communicated reallocation of resources to address COVID-19 continues to impact the timeline for completion of the review...
2021-01-12 11:50
Biovica's CEO and main shareholder Anders Rylander has, to facilitate the administration of the company's warrant program 3, lent 127,000 shares to Pareto Securities AB. The program comprises 200,000 options, of which 145,000 options have been...
2020-12-03 08:00
Convincing study results and application submitted to the FDA - commercialization just around the corner Significant events during the second quarter · Clinical validation, which is the last step required for the FDA application, has been completed...
2020-11-23 08:00
DiviTum®TKa has been selected to be included in a new prospective study of women with hormone receptor positive metastatic breast cancer. The aim of including DiviTum®TKa in the study is to investigate if this marker can be used for disease monitoring...
2020-11-20 08:00
Biovica, active in cancer diagnostics, today announced that positive DiviTum®TKa results from the European multicenter study PYTHIA will be presented at the world´s leading breast cancer conference, SABCS, in early December. The PYTHIA study...
2020-11-19 08:00
Biovica, active in cancer diagnostics, today announced that positive DiviTum®TKa results from a clinical study at the University of Nebraska Medical Center and Washington University School of Medicine, US, will be presented at the world´s leading...
2020-11-18 08:00
November 18, 2020 -- Biovica, active in cancer diagnostics, today announced that initial results from the PROMISE study (NCT03281902) will be presented at the San Antonio Breast Cancer Symposium (December 8-11, 2020). The PROMISE Study is evaluating the...
2020-11-17 15:35
Biovica, active in cancer diagnostics, today announced that new DiviTum®TKa results from a large SWOG Cancer Research Network study further strengthen DiviTum®TKa’s monitoring capabilities within metastatic breast cancer. The study, known...
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects